Cargando…
Improving the analysis of composite endpoints in rare disease trials
BACKGROUND: Composite endpoints are recommended in rare diseases to increase power and/or to sufficiently capture complexity. Often, they are in the form of responder indices which contain a mixture of continuous and binary components. Analyses of these outcomes typically treat them as binary, thus...
Autores principales: | McMenamin, Martina, Berglind, Anna, Wason, James M. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964664/ https://www.ncbi.nlm.nih.gov/pubmed/29788976 http://dx.doi.org/10.1186/s13023-018-0819-1 |
Ejemplares similares
-
Employing a latent variable framework to improve efficiency in composite endpoint analysis
por: McMenamin, Martina, et al.
Publicado: (2020) -
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial
por: McMenamin, Martina, et al.
Publicado: (2021) -
Sample size estimation using a latent variable model for mixed outcome co‐primary, multiple primary and composite endpoints
por: McMenamin, Martina E., et al.
Publicado: (2022) -
Analysis of responder-based endpoints: improving power through utilising continuous components
por: Wason, James, et al.
Publicado: (2020) -
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)